Precision Medicine
The global understanding and practice of medicine is currently undergoing a revolutionary change. This shift to precision medicine means moving healthcare from a one-size-fits-all approach to a more targeted approach, where decisions are informed by each individual’s unique clinical, molecular, and lifestyle information. Working closely together with the precision medicine community, Thermo Fisher Scientific is helping advance this revolution in diagnosis and treatment. We leverage our global infrastructure and expertise to provide industry-leading capabilities, from population profiling to targeted therapeutics.
Explore our precision medicine offerings.
Explore our scalable population-level
molecular profiling solutions designed
to deliver rapid clinical utility.
Pioneer the path from discovery to the clinic with proven platforms and cutting-edge technologies.
Discover flexible solutions for the rapid development and implementation of clinical assays.
Accelerate targeted therapeutic and
companion diagnostic development
and commercialization with our
comprehensive solutions.
Featured stories
Pharmacogenomics is Ready to Go Mainstream
In the United States , the estimated annual cost of drug-related morbidity and mortality resulting from non-optimized medication therapy amounts to 16 percent of the country’s total health care expenditures. Read how pharmacogenomics, envisions the widespread use of genetic testing to predict how patients may respond to particular medications, and is increasingly used during drug discovery and development with the promise of reducing drug-related morbidity and mortality.
The Saudi Human Genome Program: Bringing Genetic Testing to Routine Clinical Care
The Saudi Human Genome Program (SHGP) is a national project to study the genetic basis of disease in Saudi Arabia and the Middle East. This program is aimed at understanding the population’s fundamental biological makeup to help drive direct and indirect advances in medical care for decades to come by using genomic information to determine genetic risk and causality for “all health-related conditions.”
Cancer Patient Finds Hope and Remission in CAR T-Cell Therapy
Cancer patient Nicole Gularte was on hospice with only three to five weeks to live. Test results showed that she qualified for a new CAR T-cell therapy clinical trial. Learn more about this new therapy and what it means for the future of cancer treatment.
Peer inspiration
Since joining RUCDR, Dr. Andrew Brooks has worked to automate and develop the service infrastructure that provides high throughput sample management and analysis for DNA, RNA, and protein-based technologies to hundreds of labs globally.
Dr. Tim Triche, the co-director of the Center of Personalized Medicine at Children’s Hospital LA, believes that our understanding of cancer is still largely one-dimensional.
Read Interview ›
Dr. Mark Bouzyk, the co-founder and Chief
Scientific Officer of AKESOgen talks about his
work in precision medicine research.
Read Interview ›
